Navigation Links
China Cord Blood Corporation Announces Results of 2016 Annual General Meeting
Date:12/9/2016

HONG KONG, Dec. 9, 2016 /PRNewswire/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2016 Annual General Meeting, which was held on December 9, 2016, in Hong Kong S.A.R., China.

At the Annual General Meeting, shareholders

  • ratified the re-appointment of KPMG Huazhen LLP as the independent auditors of the Company for the financial year ending March 31, 2017 and authorized any duly formed committee of the directors to fix the remuneration of the independent auditors; and
  • re-elected Mr. Albert Chen and Mr. Mark D. Chen as Class A directors of the Company until the 2019 annual general meeting of the Company or until their respective successors are duly appointed and qualified.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at http://www.chinacordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the U.S. Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511 (China) or (+1) 646-405-5185 (U.S.)
Email: william.zima@icrinc.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-cord-blood-corporation-announces-results-of-2016-annual-general-meeting-300374247.html


'/>"/>
SOURCE China Cord Blood Corporation
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
2. Research on China's FISH Probe (Fluorescent in Situ Hybridization Probe) Industry, 2013-2017
3. China Diagnostic Reagent Industry Report, 2012-2014
4. China Cord Blood Corporation Received AABB Accreditation
5. Future Course of New Lethal Avian Flu Outbreak in China Can Be Predicted
6. China Industry Reports: 2013 Research on Swine Industry Chain, Human Tetanus Immunoglobulin, Power Energy Storage Battery and Wind Power Lubricating Grease at ReportsnReports.com
7. China Engineering Plastics Industry will Reach US$5 Million By 2017 - Engineering Plastics Market, Share, Size, Analysis, Market Scale, Competition and Forecast 2013-2017
8. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
9. Elsevier Signs Strategic Collaboration Agreement with Peoples Medical Publishing House, China
10. China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal 2013 Financial Results
11. Research Report on Chinas Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2018)... N.J. (PRWEB) , ... August 10, 2018 , ... Researchers ... fracturing while under pressure. The Explosion Protection Chamber for High-Pressure NMR & EPR ... new level of safety to the laboratory. , High-pressure experiments have significantly grown ...
(Date:8/9/2018)... ... August 08, 2018 , ... ActX introduces GenoACT(sm), a ... updated by a talented scientific team that includes geneticists, PharmD’s, genetic counselors, and ... Information on the medical impact of a patient’s genetic variants , 2. Educational ...
(Date:8/9/2018)... ... August 08, 2018 , ... Since their establishment in 2012, ambitions have been ... nearly double its’ size from last year, the company is thrilled to announce the ... and impressed crowds at a private product launch event during the annual Protein Society ...
(Date:8/9/2018)... ... 2018 , ... Rockland Immunochemicals, Inc. announced today that Dr. ... Antibody Development at Bio-Techne, composed a peer-reviewed article using their combined experience of ... 2018 and will be printed in the September 2018 issue by the journal ...
Breaking Biology Technology:
(Date:7/31/2018)... ... July 31, 2018 , ... ACEA Biosciences, is a ... The company has just introduced the xCELLigence RTCA S16, which the ideal entry level ... an external computer, the S16can be placed in any standard CO2 tissue culture incubator. ...
(Date:7/31/2018)... ... July 31, 2018 , ... ... Muzek as Business Development Manager. In this role, Mr. Muzek will lead the ... Lifecycle’s continued growth and expansion. , With over 20 years in business ...
(Date:7/30/2018)... ... 2018 , ... TC Slade, an evidence-based healer, today released ... treated Vitamin D3 on the strength and health of bones. , The ... ALP, a bone-specific enzyme ,     Over 240% increase in collagen levels , ...
Breaking Biology News(10 mins):